에 대한 최신 뉴스 Celanese (NYSE:CE) 주식

Celanese

Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.

Asia

Government

Regulations

Eurozone

Politics

Global

Markets

AHKSY

BASFY

MTLHY

SABRY

중국은 미국과 유럽 연합에서 만든 플라스틱에 대한 새로운 반덤핑 조사를 시작하면서 서구와의 현재 진행 중인 경제 전쟁에서 새로운 단계를 밟았다. 이번 조치는 최근 조 바이든 대통령이 주도한 중국산 수입품에 대한 관세 인상 등 서방 국가들의 최근 보호주의 조치에 대한 보복 조치로 읽힐 수 있다.

중국, 바이든의 관세에 대응하여 새로운 플라스틱 수입 조사로 반격: 6개 주식이 피해 우려

Celanese Corp

CE Energy Acquisition Corp.

CEA Industries Inc

Creations Inc

CEA Space Partners I Corp.

CENTRAL AUTOMOTIVE PRODS by Central Automotive Products Ltd.

Central Automotive Products Ltd

China Eastern Airlines Corp Ltd ADR

CHINA EVERBRIGHT BANK ORD by China Everbright Bank Co Ltd.

China Everbright Bank Co Ltd

CITYCHAMP WATCH & JEWELLE by Citychamp Watch & Jewellery Group Ltd.

Citychamp Watch & Jewellery Group Ltd

Cebu Air Inc

CANASIA ENERGY CORP by CANASIA ENERGY CORP.

CanAsia Energy Corp

Saltbae Capital Corp

Cecil Bancorp Inc

CECO Environmental Corp

Cedarlake Acquisition Corp

The Central and Eastern Europe Fund, Inc. (The) Common Stock

CENTRAL & EASTERN EUROPE FUND, INC.

Ceres Inc

CEEK VR

UpSnap Inc

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Global X S&P Catholic Values Developed ex-U.S. ETF

CENTRAL FLA ST BK BELLEVW by Central Florida State Bank (Belleview FL)

COMML NATL FINCL CRP MICH by Commercial National Financial Corp (MI)

Commercial National Financial Corp (MI)

ETRACS Monthly Pay 1.5X Leveraged Closed-End Fund Index ETN

Exchange Listed Funds Trust ETF

Constellation Energy Corporation - Common Stock

Constellation Energy Corp

CHINA ED GROUP HLDGS LTD by CHINA ED GROUP HLDGS LTD.

China Education Group Holdings Ltd

CERRO GRANDE MINING CORP by Cerro Grande Mining Corp.

Cerro Grande Mining Corp

COSMO ENERGY HLDGS CO LTD by Cosmo Energy Hldgs Co Ltd

Cosmo Energy Holdings Co Ltd

Camber Energy Inc OM PAR $0.001 2022 NEW

COMPAL ELECTRONIC 144A GDR REP 5 ORD

COELACANTH ENERGY INC by COELACANTH ENERGY INC

Coelacanth Energy Inc

Camber Energy Inc

COMPAL USD DR

CONSOL Energy Inc

CONSOL ENERGY ORD

Cresco Ltd

Celsius - United States Dollar

Celcuity Inc

Bristol-Myers Squibb Company Celegne Contingent Value Rights

Celsius Holdings Inc

CELLCOM ISRAEL LTD ORD by Cellcom Israel, Ltd.

Cellcom Israel Ltd

Cellframe

Celo

Celer Network

Centamin PLC

CENTAMIN ORD

Celularity Inc

PREFERRED COMMERCE INC by Preferred Commerce Inc.

Preferred Commerce Inc

Celexpress Inc

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Technology Holdings Inc

ClearBridge MLP & Midstream Fund Inc Com (New)

ISHRS MSCI EM ASIA UCITS USD ETF

iShares J.P. Morgan EM Corporate Bond ETF

ISHRS MSCI EM CNSMR GRWTH USD ETF

CEN Biotech Inc

Caravan Energy Corp Ordinary Shares

CareNet Inc

Cenntro Inc

CENNZnet

Central Garden & Pet Company - Common Stock

Central Garden & Pet Co

Central Garden & Pet Company - Class A Common Stock Nonvoting

Century Aluminum Co

CENTURY ALUMINUM ORD

CEO America Inc

CeCors Inc

Cantor Equity Partners, Inc. - Class A ordinary shares

Cantor Equity Partners Inc

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Central Puerto SA

Crestwood Equity Partners LP Unit Ltd Partnership Int (New)

CERES INC OM NEW

Cere Network

CERES GLOBAL AG CORP ORD by Ceres Global Ag Corp.

Ceres Global Ag Corp

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

Cerus Corp

Certara Inc

COLOMBIA ENERGY RESOUR by Colombia Energy Resources, Inc.

Colombia Energy Resources Inc

SPDR Series Trust SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF

CES ENERGY SOLUTIONS ORD by CES Energy Solutions Corp.

CES Energy Solutions Corp

FIRST TRUST GLOBAL FUNDS PLC ETF

Chesser Resources Ltd

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) rose sharply in today's session after the company reported better-than-expected fourth-quarter financial results and approved a $1 billion share buyback.
Jabil reported fourth-quarter revenue of $6.96 billion, down by 17.7% year-on-year, beating the analyst consensus estimate of $6.59 billion. The print manufacturing company's adjusted EPS of $2.30 beat the analyst consensus estimate of $2.22.
Jabil shares jumped 11.2% to $126.18 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>SBC Medical Group Holdings Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NYSE">SBC</a>) jumped 25.4% to $10.01.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares jumped 25.4% to $3.65.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 24.1% to $4.9650.</li>
<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) gained 21.7% to $10.13.</li>
<li>Ispire Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) surged 18.6% to $6.91 following FY24 financial results.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 17.8% to $7.43.</li>
<li>KE Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) surged 17.4% to $19.22. Shares of Chinese stocks traded higher following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) gained 16.7% to $36.60. Shares of Chinese stocks traded higher following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) gained 14.4% to $71.19.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 14.2% to $109.37 following strong quarterly results.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) jumped 14.2% to $43.60.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 10% to $100.78.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) climbed 9.9% to $31.19 after the company announced it plans a $2.5 billion share repurchase program and issued its third-quarter RASM guidance. Also, the company announced it reduced headcount through controlled hiring and attrition and has contracts with all labor groups.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) gained 9.7% to $104.73 following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) rose 9.1% to $55.74.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) gained 6.6% to $138.71.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045737/top-3-materials-stocks-youll-regret-missing-this-quarter">Top 3 Materials Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

News

Pre-Market Outlook

Movers

Trading Ideas

ADPT

BABA

BEKE

New Oriental Education & Technology Group

GSX Techedu Inc. American Depositary Shares

GOTU

HTHT

ISPR

TCOM

YUMC

Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Piper Sandler cut the price target for C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from $29 to $24. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. C3.ai shares fell 1.9% to close at $23.01 on Wednesday. <a href="https://www.benzinga.com/quote/AI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised the price target for Collegium Pharmaceutical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) from $47 to $50. HC Wainwright &amp; Co. analyst Oren Livnat maintained a Buy rating. Praxis Collegium Pharmaceutical shares gained 2.2% to close at $38.24 on Wednesday. <a href="https://www.benzinga.com/quote/COLL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) price target from $3 to $2. Needham analyst Chris Pierce maintained a Buy rating. ChargePoint shares fell 0.6% to close at $1.69 on Wednesday. <a href="https://www.benzinga.com/quote/CHPT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $530 to $564. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 0.5% to close at $513.31 on Wednesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $130 to $68. BMO Capital analyst Kelly Bania downgraded the stock from Outperform to Market Perform. Dollar Tree shares fell 22.2% to close at $63.56 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) price target from $119 to $121. Goldman Sachs analyst James Quigley downgraded the stock from Buy to Neutral. Novartis shares rose 0.7% to close at $119.38 on Wednesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Core &amp; Main, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) price target from $62 to $53. Baird analyst David Manthey maintained an Outperform rating. Core &amp; Main shares fell 15.8% to close at $39.40 on Wednesday. <a href="https://www.benzinga.com/quote/CNM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna slashed the price target for EVERTEC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from $38 to $28. Susquehanna analyst James Friedman downgraded the stock from Neutral to Negative. EVERTEC shares rose 0.3% to close at $33.73 on Wednesday. <a href="https://www.benzinga.com/quote/EVTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) price target from $180 to $150. Piper Sandler analyst Charles Neivert downgraded the stock from Overweight to Neutral. Celanese shares fell 0.8% to close at $124.31 on Wednesday.<a href="https://www.benzinga.com/quote/CE/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Morgan Stanley lowered StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) price target from $16.5 to $7. Morgan Stanley analyst Jorge Kuri downgraded the stock from Equal-Weight to Underweight. StoneCo shares fell 3.8% to close at $12.61 on Wednesday.<a href="https://www.benzinga.com/quote/STNE/analyst-ratings"> See how other analysts view this stock.</a></li>
</ul>
Considering buying SPGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-1024x522.png" alt="" class="wp-image-531810" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36.png 1321w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Price Target

Analyst Ratings

CHPT

COLL

DLTR

EVTC

SPGI

STNE

S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

In the preceding three months, 17 analysts have released ratings for Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Celanese, presenting an average target of $155.65, a high estimate of $184.00, and a low estimate of $128.00. Experiencing a 8.06% decline, the current average is now lower than the previous average price target of $169.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1725537687_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Celanese among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$128.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$138.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$184.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$158.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$144.00</td>
<td>$147.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Celanese's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celanese analyst ratings.</a>
<h2>About Celanese</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Key Indicators: Celanese's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Celanese's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.15% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Celanese's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.18%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celanese's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.87, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 17 Ratings For Celanese

Piper Sandler analyst Charles Neivert downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Overweight to Neutral and lowers the price target from $180 to $150.

Downgrades

Piper Sandler Downgrades Celanese to Neutral, Lowers Price Target to $150

Deutsche Bank analyst David Begleiter maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Hold and lowers the price target from $160 to $135.

Deutsche Bank Maintains Hold on Celanese, Lowers Price Target to $135

B of A Securities analyst Steve Byrne maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Underperform and lowers the price target from $137 to $128.

B of A Securities Maintains Underperform on Celanese, Lowers Price Target to $128

RBC Capital analyst Arun Viswanathan maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $168 to $167.

RBC Capital Maintains Outperform on Celanese, Lowers Price Target to $167

BMO Capital analyst John McNulty maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Market Perform and lowers the price target from $142 to $138.

BMO Capital Maintains Market Perform on Celanese, Lowers Price Target to $138

Barclays analyst Michael Leithead maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $170 to $151.

Barclays Maintains Equal-Weight on Celanese, Lowers Price Target to $151

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5dfa5c7f3513fb0001efbfda/ken-herbert">RBC Capital analyst Ken Herbert</a> upgraded the rating for Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) from Sector Perform to Outperform, while raising the price target from $500 to $600. Lockheed Martin shares gained 2.4% to trade at $562.00 on Monday. <a href="https://www.benzinga.com/quote/LMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df22a3dbffdfc0001d6fa45/christopher-allen">Citigroup analyst Christopher Allen </a>upgraded Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Sell to Neutral and announced a price target of $18. Robinhood shares fell 21% to trade at $14.13 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/topic/bose-george">Keefe, Bruyette &amp; Woods analyst Bose George </a>upgraded Essent Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) from Market Perform to Outperform and raised the price target from $65 to $70. Essent Group shares fell 2.1% to trade at $58.72 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/topic/nikolay-beliov">B of A Securities analyst Nikolay Beliov </a>upgraded the rating for Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from Underperform to Buy and maintained the price target of $63. Five9 shares fell 1.6% to trade at $40.13 on Monday. <a href="https://www.benzinga.com/quote/FIVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5841bdbcaae83900016b3c7a/jeffrey-zekauskas">JP Morgan analyst Jeffrey Zekauskas </a>upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Underweight to Neutral, but lowered the price target from $156 to $130. Celanese shares fell 4.4% to trade at $131.55 on Monday. See how other analysts view this stock. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Upgrades

ESNT

FIVN

HOOD

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wells Fargo analyst Michael Sison maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Overweight and lowers the price target from $180 to $165.

Wells Fargo Maintains Overweight on Celanese, Lowers Price Target to $165

Throughout the last three months, 15 analysts have evaluated Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.27, a high estimate of $184.00, and a low estimate of $130.00. A decline of 3.2% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1722859256_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Celanese by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$184.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$158.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$144.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$158.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$176.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Kieran De Brun</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$161.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celanese. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Celanese's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Celanese's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celanese analyst ratings.</a>
<h2>Get to Know Celanese Better</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Celanese: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Celanese's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 1.53%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Celanese's net margin is impressive, surpassing industry averages. With a net margin of 5.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Celanese's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.18%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.6%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 1.86, Celanese faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Celanese: Insights From 15 Financial Analysts

Keybanc analyst Aleksey Yefremov maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Overweight and lowers the price target from $180 to $178.

Keybanc Maintains Overweight on Celanese, Lowers Price Target to $178

Baird analyst Ghansham Panjabi maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $180 to $150.

Baird Maintains Outperform on Celanese, Lowers Price Target to $150

JP Morgan analyst Jeffrey Zekauskas upgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Underweight to Neutral and lowers the price target from $156 to $130.

JP Morgan Upgrades Celanese to Neutral, Lowers Price Target to $130

Celanese Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ce#NYSE">CE</a>) reported second-quarter 2024 earnings from continuing operations of $1.42 per share, which declined from $2 in the prior-year quarter.
Adjusted earnings were $2.38 per share, up 9.7% from $2.17 reported a year ago. The bottom line lagged the Zacks Consensus Estimate of $2.80.
Revenues of $2,651 million decreased roughly 5.1% year over year. It missed the Zacks Consensus Estimate of $2,725.7 million. The decline in net sales is a result of a decrease in pricing.
<div class="chart_embed">
<h3>Celanese Corporation Price, Consensus and EPS Surprise</h3>
<h3><img alt="Celanese Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/e0/1722590652.png" style="height:265px; width:591px" title="" /></h3>
Celanese Corporation price-consensus-eps-surprise-chart | Celanese Corporation Quote
</div>
<h3>Segment Highlights</h3>
Net sales in the Engineered Materials unit were $1,467 million in the reported quarter, down around 7.4% year over year. It missed our estimate of $1,648.4 million. The segment reported an operating profit of $138 million and an adjusted EBIT of $265 million in the second quarter.
The Acetyl Chain segment posted net sales of $1,202 million, down roughly 2.5% year over year. It beat our estimate of $1,125.1 million. The segment generated an operating profit of $242 million and an adjusted EBIT of $277 million in the second quarter.
<h3>Financials</h3>
Celanese ended the quarter with cash and cash equivalents of $1,185 million, down roughly 8.5% sequentially. Long-term debt was stable sequentially at $11,058 million.
Cash provided by operating activities was $292 million and free cash flow was $173 million in the reported quarter. Capital expenditures were $105 million.
<h3>Outlook</h3>
Celanese expects adjusted earnings in the range of $2.75-$3 per share for the third quarter of 2024. Furthermore, based on the impact of the second-quarter force majeure and ongoing demand issues, CE forecasts full-year adjusted earnings per share in the range of $10.25 to $10.75.
<h3>Price Performance</h3>
Celanese&#39;s shares have gained 10.6% in the past year against a 11.4% decline of the industry.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/7c/73180.jpg?v=1554293826" />
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Key Picks</h3>
CE currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks worth a look in the basic materials space include Barrick Gold Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gold#NYSE">GOLD</a>), Hecla Mining Company&nbsp;and SilverCrest Metals Inc. (AMEX:SILV).
Barrick is slated to report second-quarter results on Aug 12, before market open. The Zacks Consensus Estimate for GOLD&#39;s earnings is pegged at 26 cents. GOLD beat the consensus in each of the last four quarters, with the average earnings surprise being 18.3%. GOLD currently carries a Zacks Rank #2 (Buy).
Hecla, carrying a Zacks Rank #1, is slated to report second-quarter results on Aug 6. The Zacks Consensus Estimate for Hecla&#39;s second-quarter earnings is pegged at a penny per share. The stock has gained nearly 0.8% in the past year.
SilverCrest will report results for the second quarter on Aug 7. The Zacks Consensus Estimate for SilverCrest&#39;s earnings is pegged at 17 cents. SILV, a Zacks Rank #2 stock, beat the consensus in each of the last four quarters, with the average earnings surprise being 42.4%. The stock has surged nearly 107% in the past year.&nbsp;
<a href="https://www.zacks.com/stock/news/2314916/celanese-ce-q2-earnings-and-sales-fall-short-of-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-2314916">To read this article on Zacks.com click here.</a>

Earnings

Earnings Misses

GOLD

SILV

Celanese Q2 Earnings and Sales Fall Short of Estimates

WIIM

Celanese shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company issued Q3 and FY24 EPS guidance below estimates.

Outlook
"We are encouraged to see the tangible realization of our value creation initiatives in our second quarter results, and we are confident that those benefits will continue through the year," said Lori Ryerkerk. "Given the continued lack of evidence of meaningful demand recovery and the increasing pricing pressure from this low demand environment, our focus will remain on what we can control to deliver a sustainable earnings lift for Celanese. We expect the third quarter will bring an easing of the effects of the force majeure, and further improvements to our business driven by our action plans. Because of our foundational value creation initiatives, I am confident we will continue to deliver improved earnings performance in the third quarter and through the remainder of the year."
The Company anticipates third quarter adjusted earnings per share of $2.75 to $3.00. Furthermore, based on the effects of the second quarter force majeure and persistent demand challenges, the Company anticipates full year adjusted earnings per share of $10.25 to $10.75.
Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.

Guidance

Celanese Sees Q3 EPS $2.75-$3.00 Vs $3.19 Est.; FY24 EPS $10.25-$10.75 Vs $11.11 Est.

Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) reported quarterly earnings of $2.38 per share which missed the analyst consensus estimate of $2.71 by 12.18 percent. This is a 9.68 percent increase over earnings of $2.17 per share from the same period last year. The company reported quarterly sales of $2.65 billion which missed the analyst consensus estimate of $2.75 billion by 3.74 percent. This is a 5.15 percent decrease over sales of $2.79 billion the same period last year.

Celanese Q2 Adj $2.38 Misses $2.71 Estimate, Sales $2.65B Miss $2.75B Estimate

ACNT

ALTO

PACK

PPTA

Shares of companies within the broader materials sector are trading higher following recent CPI data.

RSPM: Materials Dashboard For August

S&P 500 buy and sell ideas for each of the sectors - Oppenheimer

Celanese downgraded at Piper Sandler on global weakness

Russell companies with the lowest tax rates expected to generate $1B in 2025 – GS

The latest update is out from Celanese ( ($CE) ). Celanese Corporation, a global chemical and specialty materials company, has announced the additi...

Comments

Celanese

뉴스

에 대한 최신 뉴스 Celanese (NYSE:CE) 주식

월요일, 5월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌